Gimeracil丨CAS 103766-25-2

Gimeracil丨CAS 103766-25-2
Product Introduction:
Catalog No.: SS126730
CAS No.: 103766-25-2
Purity: 99.7%min
Product Name: Gimeracil
Molecular Formula: C5H4ClNO2
Molecular Weight: 145.54
Synonym(s): Gimestat; 5-Chloropyridine-2,4-diol
Send Inquiry
Technical Parameters
Description

Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of gimeracil丨cas 103766-25-2 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.

 

Specifications

 

Appearance

White to pale yellow crystalline powder

Purity

99.7% min

Identification

Maximum wavelength absorption at 289 nm

Individual impurity

0.1% max

Total impurities

0.3% max

Loss on drying

1.0% max

Residue on ignition

0.2% max

 

Transport Information

 

Parameter

Specification

UN Number

 

Class

 

Packing Group

 

H.S. Code

2933990099306

Stability & Reactivity

The product is chemically stable under standard ambient conditions.

Storage

Tightly closed. Dry. Storage stability Recommended storage temperature -20 °C

Condition to Avoid

 

Package

 

 

Manufacturing Information

 

Parameter

Specification

Capacity

 

Frequency

 

Main Export Countries

 

Capacity/Batch

 

Experience

Production since 2015

Stock

 

Introduction

 

Gimeracil丨CAS 103766-25-2 is a pharmacologically active compound primarily known as a potent inhibitor of dihydropyrimidine dehydrogenase (DPD) - the enzyme responsible for the catabolism of 5-fluorouracil (5-FU) and related fluoropyrimidine drugs. By inhibiting DPD, gimeracil increases the bioavailability and therapeutic efficacy of 5-FU, making it an important agent in cancer chemotherapy.
Gimeracil is a key component of the oral anticancer drug S-1, a combination formulation containing tegafur, gimeracil, and oteracil potassium, designed to enhance 5-FU effectiveness while reducing toxicity.

 

Applications

 

1. Cancer Chemotherapy
● Enhancer of fluoropyrimidine drugs: Gimeracil丨CAS 103766-25-2 is used to inhibit DPD, slowing the breakdown of 5-FU in the body.
● This prolongs the plasma concentration of 5-FU, enhancing its anticancer activity against solid tumors, such as colorectal, gastric, pancreatic, and head & neck cancers.
● Improves efficacy of oral 5-FU prodrugs (like tegafur) by maintaining therapeutic drug levels.
2. Combination Drug Formulations
● Integral part of the S-1 formulation (Tegafur + Gimeracil + Oteracil potassium), used widely in Asia and increasingly globally.
● S-1 provides oral administration convenience, better patient compliance, and reduced side effects compared to intravenous 5-FU therapy.
3. Pharmacokinetic Modulator
● Modulates the pharmacokinetics of fluoropyrimidines, leading to improved dose control and reduced variability in drug exposure.
● Helps tailor cancer therapy regimens to maximize efficacy and minimize toxicity.

 

Benefits

 

1. Increased Efficacy of Chemotherapy
● By inhibiting DPD, gimeracil enhances the concentration and duration of 5-FU in the plasma.
● This leads to stronger antitumor effects and potentially improved patient outcomes.
2. Oral Drug Convenience
● Enables effective oral fluoropyrimidine chemotherapy, offering better quality of life compared to intravenous treatments.
● Facilitates outpatient treatment and reduces hospital visits.
3. Reduced Side Effects
● By controlling 5-FU levels more precisely, it helps to mitigate common toxicities like hand-foot syndrome, gastrointestinal irritation, and myelosuppression.
● Contributes to a more manageable safety profile in cancer patients.
4. Pharmacological Specificity
● Gimeracil selectively inhibits DPD without affecting other enzymes, leading to targeted pharmacokinetic modulation.
● Minimizes off-target effects.

 

Conclusion

 

Gimeracil丨CAS 103766-25-2 is a critical DPD inhibitor used to enhance the therapeutic efficacy of 5-fluorouracil and related anticancer drugs. Its role in oral chemotherapy formulations such as S-1 represents a significant advancement in cancer treatment by improving drug bioavailability, efficacy, and patient convenience while reducing toxicity. Gimeracil continues to be a key agent in modern oncology, contributing to better cancer management outcomes.

 

Send Inquiry
Beyond Your Expectation
From Science to Life with LEAPChem
contact us